Innovation Event

Overview

Category: Life Sciences

Place: Halle 7, Gundeldingerfeld, Dornacherstrasse 192, 4053 Basel

Gabriela Güntherodt

Your contact person

Gabriela Güntherodt

Member of the Management Board, Head of International Markets & Promotion

Contact us
event Life Sciences

08.06.2017

The future of biomedical research in Europe

The growth and success of biomedical research is vital for Europe. We’d like to invite you to an evening where we’ll consider the future of biomedical research in Europe, and whether enough is being done to attract and foster companies that could – in the near future – transform the European economy.

To discuss these important issues, BaselArea.swiss has partnered with an innovative biopharmaceutical company, Roivant Sciences, that recently established its global headquarters in Basel. Beginning with the opportunity to develop a Phase 3 drug for Alzheimer’s disease, Vivek Ramaswamy, the Founder and CEO of Roivant Sciences, founded the company with the mission of systematically reducing the time, cost and risk of bringing new drugs to market – and sharing these savings with the healthcare system. Three years later, Roivant has founded five companies in areas ranging from women’s health to rare diseases, and supports a pipeline of 14 clinical assets in development.

Joining Mr. Ramaswamy on the panel:

Dr. David T. Hung recently became CEO of Axovant Sciences, the neurology company founded by Roivant Sciences to develop treatments for dementia and other neurological conditions. Dr. Hung was previously the founder of Medivation, the company that developed XTANDI and was subsequently acquired by Pfizer in 2016 for $14 billion.

Dr. Vas Narasimhan has been Global Head of Drug Development and Chief Medical Officer for Novartis since February 1, 2016. In his current role, Dr. Narasimhan leads drug development for Novartis’ innovative medicines and biosimilars portfolio. He is a member of the Executive Committee of Novartis. In January 2017, he became a member of the Board of Trustees of the Novartis Foundation.

Dr. Jonathan Knowles has been a Non-Executive Director of Immunocore since 2010 and became Executive Chairman in November 2013. He was formerly President of Group Research and a Member of the Executive Committee at F. Hoffman-LaRoche Ltd, Basel, Switzerland for 12 years. Dr. Knowles also served as a Board Member at Genentech Inc. for over 10 years and was a Member of the Board of Chugai Pharmaceuticals.

The conference will take place June 8th, 2017 at Halle 7 (Dornacherstrasse 192) in Basel, starting at 17:30.

Program:

17:30 Reception
17:50 Welcome: Alethia de Leon, Managing Director, BaseLaunch
18:00 Keynote: Vivek Ramaswamy, Founder and CEO, Roivant Sciences
18:30

The future of biomedical research in Europe
Panel:
Vivek Ramaswamy – Founder and CEO, Roivant Sciences
David Hung – CEO, Axovant Sciences
Vas Narasimhan – Global Head of Drug Development and CMO, Novartis
Jonathan Knowles – Chairman, Immunocore
Moderator: Alethia de Leon, Managing Director, BaseLaunch

19:30 Closing & networking apéro


Participation is free of charge. However, we ask that you please register on the right handside no later than May 26th, 2017.

We look forward to seeing you soon!

 

About the speakers:

Vivek Ramaswamy
Founder and CEO, Roivant Sciences

Vivek Ramaswamy is founder and Chief Executive Officer of Roivant Sciences, Inc., and the founder and former Chief Executive Officer of Axovant Sciences, Inc. Prior to founding Roivant, Mr. Ramaswamy was a well-known investor in the biotechnology sector. In 2007, he co-founded and served as President of Campus Venture Network, a technology company that was acquired in 2009. He currently serves as Chairman of the Board of Directors of Arbutus Biopharma Corporation and a member of the Board of Directors of Axovant Sciences Ltd., Myovant Sciences Ltd., and Roivant Sciences Ltd. He received an A.B. summa cum laude in biology from Harvard College and a J.D. from Yale Law School.

David T. Hung, MD
CEO, Axovant Sciences

Dr. Hung has served as Chief Executive Officer and as a member of the Board of Axovant Sciences since April 2017. Previously, Dr. Hung was a co-founder of Medivation, Inc., a biopharmaceutical company, and served as its President and Chief Executive Officer and as a member of its board of directors, from December 2004 until its acquisition by Pfizer Inc. in September 2016. From 1998 until 2001, Dr. Hung was employed by ProDuct Health, Inc., a privately held medical device company, as Chief Scientific Officer and then as President and Chief Executive Officer. Dr. Hung served as a consultant to Cytyc Corporation from 2001 until 2002 to assist with transitional matters related to Cytyc Corporation’s acquisition of ProDuct Health, Inc. Dr. Hung served as a member of the board of directors of Opexa Therapeutics, Inc., a biopharmaceutical company, from May 2006 to October 2011. Dr. Hung received an MD from the University of California, San Francisco, School of Medicine, and an AB in Biology from Harvard College.

Vas Narasimhan, MD
Global Head of Drug Development and Chief Medical Officer for Novartis

Vas Narasimhan, M.D., has been Global Head of Drug Development and Chief Medical Officer for Novartis since February 1, 2016. He is a member of the Executive Committee of Novartis. In January 2017, he became a member of the Board of Trustees of the Novartis Foundation. Dr. Narasimhan joined Novartis in 2005 and has held numerous leadership positions in development and commercial functions. His most recent role was Global Head of Development for Novartis Pharmaceuticals, overseeing the entire general medicines pipeline. He previously served as Global Head of the Sandoz Biopharmaceuticals and Oncology Injectables business unit, overseeing the division’s biosimilars pipeline, and as Global Head of Development for Novartis Vaccines. Dr. Narasimhan has also held commercial and strategic roles at Novartis, including North America Region Head for Novartis Vaccines, and United States Country President for Novartis Vaccines and Diagnostics. Before joining Novartis, he worked at McKinsey & Company. Dr. Narasimhan received his medical degree from Harvard Medical School in the US and obtained a master’s degree in public policy from Harvard’s John F. Kennedy School of Government. He received his bachelor’s degree in biological sciences from the University of Chicago, also in the US. He is an elected member of the US National Academy of Medicine.

Dr. Jonathan Knowles
Chairman, Immunocore

Dr. Jonathan Knowles has been a Non-Executive Director of Immunocore since 2010 and became Executive Chairman in November 2013. He was formerly President of Group Research and a Member of the Executive Committee at F. Hoffman-LaRoche Ltd, Basel, Switzerland for 12 years. Dr. Knowles also served as a Board Member at Genentech Inc. for over 10 years and was a Member of the Board of Chugai Pharmaceuticals, Tokyo, Japan. Prior to joining Roche in 1997, he was Research Director at Glaxo Wellcome Europe. Dr. Knowles has also served as Chairman of the Hever Group and the EFPIA Research Directors Group. He was instrumental in creating the Innovative Medicines Initiative (IMI) and was the first Chairman of the Board of IMI (a Joint Undertaking with the EU Commission). He is a Distinguished Professor (FiDiPro) at the University of Helsinki, Finland, holds a visiting chair at the University of Oxford, and is a visiting scholar of Pembroke College, Cambridge. In 2017, Dr. Knowles was recognised for his contribution to medical science with an election to the Fellowship of the Academy of Medical Sciences.

About the moderator:

Alethia de Leon
Managing Director, BaseLaunch

Alethia de Leon has been leading the Basel Life Sciences Accelerator from within BaselArea.swiss since September 2016. She is also the CEO and founder of Senes Science GmbH, developing medical technologies to improve the quality of life for the elderly. Previously, she headed the global search and evaluation of business development activities for the Neuroscience Unit of Novartis Pharmaceuticals AG. She was also part of the strategy team of Novartis Pharmaceuticals, before which she also had roles in smaller biotech organizations and in process development and led biotech investments for a private equity fund. Alethia de Leon holds an MBA from Harvard Business School and Master’s and Bachelor’s degrees in Chemical Engineering from the Massachusetts Institute of Technology.

Hosted by:

Gabriela Güntherodt

Your contact person

Gabriela Güntherodt

Member of the Management Board, Head of International Markets & Promotion

Contact us
Cookies

BaselArea.swiss uses cookies to ensure you get the best service on our website.
By continuing to browse the site, you are agreeing to the use of cookies.

Ok